Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2014; 20(1): 235-241
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.235
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.235
Table 4 Toxicity profiles n (%)
Grade 1/2 | Grade 3/4 | Total | |
Hematologic | |||
Anemia | 72 (70.6) | 10 (9.8) | 82 (80.4) |
Neutropenia | 15 (14.7) | 55 (53.9) | 70 (68.6) |
Thrombocytopenia | 61 (59.8) | 28 (27.4) | 89 (87.2) |
Non-Hematologic | |||
Nausea | 4 (3.9) | 0 | 4 (3.9) |
Vomiting | 2 (1.9) | 0 | 2 (1.9) |
Asthenia | 24 (23.5) | 3 (2.9) | 27 (26.4) |
Anorexia | 2 (1.9) | 0 | 2 (1.9) |
Microsites | 6 (5.8) | 0 | 6 (5.8) |
- Citation: Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol 2014; 20(1): 235-241
- URL: https://www.wjgnet.com/1007-9327/full/v20/i1/235.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i1.235